Jazz Pharmaceuticals plc (JAZZ): Long-Term Debt
$5.36B
As of 2025-12-31
$4.35B
As of 2026-06-30
-2.2%
3-year compound annual growth
+20.7%
5-year compound annual growth
+16.3%
10-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.36B | -12.3% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $6.11B | +6.9% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $5.71B | -0.2% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $5.72B | -5.4% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $6.05B | +188.8% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $2.09B | +30.3% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $1.61B | +0.7% | 2021-02-23, Balance as of period end |
| 2018-12-31 | $1.60B | +1.0% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $1.58B | -22.1% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $2.03B | +70.8% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $1.19B | n/c | 2017-02-28, Balance as of period end |
| 2014-12-31 | $1.34B | +144.1% | 2016-02-23, Balance as of period end |
| 2013-12-31 | $549.98M | n/a | 2015-02-24, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $5.36B | -12.3% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $3.76B | -12.9% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $836.37M | n/a |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $2.57B | +7.8% |
| Organon & Co. (OGN) | 2025-12-31 | $8.64B | -2.7% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $8.95B | +17.6% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $828.97M | n/a |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $20.82B | -3.7% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $993.95M | +0.2% |
Compare JAZZ, ELAN, ONC, AMRX side by side · Screen every company in Pharmaceutical Preparations ↗